ADM Tronics Reports First Quarter of Fiscal Year 2025 Results
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reports positive financial results for the first quarter of Fiscal Year 2025 ended June 30, 2024. Key highlights include:
- Revenue increased by 12% to $857,845 compared to $762,689 in the same period last year
- Net profit of $272,168, a significant improvement from a net loss of $132,261 in the previous year
- Profit from operations of $164,281, compared to a loss of $137,796 in the same quarter last year
- Gross profit increased to $520,903 from $325,142
ADMT completed R&D for its Vet-Sonotron® device and is advancing the human medical version. The company plans to pursue FDA 510(k) submission for the human Sonotron®, targeting non-drug pain treatment.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) riporta risultati finanziari positivi per il primo trimestre dell'anno fiscale 2025, conclusosi il 30 giugno 2024. I punti salienti includono:
- Ricavi aumentati del 12% a $857,845, rispetto a $762,689 nello stesso periodo dell'anno scorso
- Utili netti di $272,168, un miglioramento significativo rispetto a una perdita netta di $132,261 nell'anno precedente
- Profitto operativo di $164,281, rispetto a una perdita di $137,796 nello stesso trimestre dell'anno scorso
- Il profitto lordo è aumentato a $520,903 da $325,142
ADMT ha completato la R&S per il suo dispositivo Vet-Sonotron® e sta sviluppando la versione umana. L'azienda prevede di presentare la domanda FDA 510(k) per il Sonotron® umano, mirando a un trattamento del dolore non farmacologico.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) informa sobre resultados financieros positivos para el primer trimestre del año fiscal 2025 que finalizó el 30 de junio de 2024. Los aspectos destacados incluyen:
- Los ingresos aumentaron un 12% a $857,845 en comparación con $762,689 en el mismo período del año pasado
- Beneficio neto de $272,168, una mejora significativa respecto a una pérdida neta de $132,261 del año anterior
- Beneficio operativo de $164,281, en comparación con una pérdida de $137,796 en el mismo trimestre del año pasado
- El beneficio bruto aumentó a $520,903 desde $325,142
ADMT ha completado la I+D para su dispositivo Vet-Sonotron® y está avanzando en la versión médica humana. La compañía planea presentar la solicitud FDA 510(k) para el Sonotron® humano, buscando un tratamiento del dolor no farmacológico.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT)는 2025 회계연도 첫 분기(2024년 6월 30일 마감)에 대한 긍정적인 재무 결과를 보고했습니다. 주요 하이라이트는 다음과 같습니다:
- 수익이 12% 증가하여 $857,845로, 지난해 같은 기간의 $762,689와 비교됩니다.
- 순이익은 $272,168으로, 지난해의 순손실 $132,261에서 크게 개선되었습니다.
- 영업이익은 $164,281으로, 지난해 같은 분기에서의 손실 $137,796과 비교됩니다.
- 총이익은 $520,903에서 $325,142로 증가했습니다.
ADMT는 Vet-Sonotron® 장치의 연구개발을 완료했으며, 인간 의학 버전으로 나아가고 있습니다. 회사는 비약물 통증 치료를 목표로 하는 인간 Sonotron®에 대해 FDA 510(k) 제출을 추진할 계획입니다.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) rapporte des résultats financiers positifs pour le premier trimestre de l'exercice fiscal 2025, qui s'est terminé le 30 juin 2024. Les principaux points forts incluent :
- Les revenus ont augmenté de 12% pour atteindre 857 845 $, contre 762 689 $ au cours de la même période l'an dernier
- Bénéfice net de 272 168 $, une amélioration significative par rapport à une perte nette de 132 261 $ l'année précédente
- Bénéfice d'exploitation de 164 281 $, comparé à une perte de 137 796 $ au même trimestre l'année précédente
- Le bénéfice brut a augmenté à 520 903 $ contre 325 142 $
ADMT a terminé la R&D de son appareil Vet-Sonotron® et fait avancer la version médicale humaine. La société prévoit de faire une demande de soumission FDA 510(k) pour le Sonotron® humain, visant un traitement de la douleur sans médicaments.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) berichtet über positive Finanzresultate für das erste Quartal des Geschäftsjahres 2025, das am 30. Juni 2024 endete. Wichtige Highlights sind:
- Umsatz steigerte sich um 12% auf $857,845 im Vergleich zu $762,689 im gleichen Zeitraum des Vorjahres
- Nettoergebnis von $272,168, eine deutliche Verbesserung gegenüber einem Nettverlust von $132,261 im Vorjahr
- Betriebsgewinn von $164,281, im Vergleich zu einem Verlust von $137,796 im gleichen Quartal des Vorjahres
- Bruttoertrag erhöhte sich auf $520,903 von $325,142
ADMT hat die Forschung und Entwicklung für sein Vet-Sonotron®-Gerät abgeschlossen und treibt die menschliche medizinische Version voran. Das Unternehmen plant, einen Antrag auf FDA 510(k) für das menschliche Sonotron® einzureichen, um eine nicht-medikamentöse Schmerzbehandlung anzustreben.
- Revenue increased by 12% year-over-year to $857,845
- Net profit of $272,168 compared to a net loss of $132,261 in the previous year
- Profit from operations of $164,281, a 119% increase from the previous year's loss
- Gross profit increased to $520,903 from $325,142
- Completed R&D for Vet-Sonotron® device and advancing human medical version
- R&D expenses remained relatively unchanged at $127,993
NORTHVALE, NJ / ACCESSWIRE / August 19, 2024 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2024 of Fiscal Year 2025.
ADMT achieved a profit for the first quarter of Fiscal Year 2025, as compared to loss for the same period last year. Revenues increased over
ADMT completed R&D and engineering efforts of its' Vet-Sonotron ® non-invasive pain treatment device for the veterinary market during the last quarter of fiscal year ended March 31, 2024. (www.vet-sonotron.com) The Company then directed additional R&D and engineering activities to advance the development of the human medical version of this innovative therapeutic technology. As a result, R&D expense for the quarter ended June 30, 2024 was comparable to the same period last year. The Company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Sonotron ® is being developed for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet.
Revenues for the quarter ended June 30, 2024, were
Financial Highlights
| Three Months Ended |
| Three Months Ended |
| ||
| June 30, 2024 |
| June 30, 2023 |
| ||
Net Revenues | $ | 857,845 |
| $ | 762,689 |
|
|
|
|
|
|
|
|
Cost of sales |
| 336,942 |
|
| 437,547 |
|
|
|
|
|
|
|
|
Gross Profit |
| 520,903 |
|
| 325,142 |
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
Research and development |
| 127,993 |
|
| 130,587 |
|
Selling, general and administrative |
| 228,629 |
|
| 332,351 |
|
Total operating expenses |
| 356,622 |
|
| 462,938 |
|
|
|
|
|
|
|
|
Profit (loss) from operations |
| 164,281 |
|
| (137,796 | ) |
|
|
|
|
|
|
|
Total other income |
| 108,387 |
|
| 5,535 |
|
|
|
|
|
|
|
|
Profit (loss) before provision for income taxes |
| 272,668 |
|
| (132,261 | ) |
|
|
|
|
|
|
|
Total benefit (provision) for income taxes |
| 500 |
|
| - |
|
|
|
|
|
|
|
|
Net profit (loss) | $ | 272,168 |
| $ | (132,261 | ) |
|
|
|
|
|
|
|
Basic and diluted earnings (loss) per common share | $ | 0.00 |
| $ | (0.00 | ) |
Weighted average shares of common stock outstanding - basic and diluted |
| 67,588,492 |
|
| 67,588,492 |
|
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.
To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/
Sonotron ® is a registered trademark of ADM Tronics Unlimited, Inc.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
For more information - Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET
Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on accesswire.com
FAQ
What was ADMT's revenue for Q1 FY2025?
How much profit did ADMT report for Q1 FY2025?
What is the status of ADMT's Vet-Sonotron device development?
Is ADMT planning to seek FDA approval for its Sonotron device?
